A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, CROSSOVER STUDY OF THE EFFECT OF ZT-01 ON FREQUENCY OF NOCTURNAL HYPOGLYCEMIA IN TYPE 1 DIABETES MELLITUS

Intervention/treatment:
AXAREOTIDE ACETATE (ZT-01)
Medical condition:
TYPE 1 DIABETES
Protocol code:
ZT01-CL-2001
Control number:
274563
Status:
Recruiting
Approved:
May 19, 2023
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05762107
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
ZUCARA THERAPEUTICS INC.

Locations

Alberta

Centricity Research Calgary Endocrinology
Calgary, Alberta, T2H 2G4
RECRUITING
Name
Buki Ajala, MBBS
Role
CONTACT
Phone:
403-288-3224
Name
Buki Ajala, MBBS
Role
PRINCIPAL_INVESTIGATOR
Richmond Road Diagnostic & Treatment Centre, Clinical Trials Unit
Calgary, Alberta, T2T5C7
RECRUITING
Name
Michelle Smith
Role
CONTACT
Phone:
4039558117
Name
Ronald Sigal, MD
Role
PRINCIPAL_INVESTIGATOR

British Columbia

BC Diabetes
Vancouver, British Columbia, V5Y 3W2
RECRUITING
Name
Alireza Moshiri
Role
CONTACT
Phone:
604-628-7253
Name
Thomas Elliott, MBBS
Role
PRINCIPAL_INVESTIGATOR

Ontario

Centricity Research Barrie Endocrinology
Barrie, Ontario, L4N 7L3
WITHDRAWN
Name
Sanjida Nishat
Role
CONTACT
Phone:
905-288-5667
Extension 4296
Name
Robert Schlosser, MD
Role
PRINCIPAL_INVESTIGATOR
Centricity Research Etobicoke Endocrinology
Etobicoke, Ontario, M9R 4E1
RECRUITING
Name
Sneha Sharma
Role
CONTACT
Phone:
416-645-1035
Name
Hasnain Khandwala, MBBS
Role
PRINCIPAL_INVESTIGATOR
Centricity Research Toronto
Toronto, Ontario, M4G 3E8
RECRUITING
Name
Janessa Gabuyo
Role
CONTACT
Phone:
647-374-5285
Extension 7625
Name
Alexander Abitbol, MDCM
Role
PRINCIPAL_INVESTIGATOR
Centricity Research Vaughan Endocrinology
Concord, Ontario, L4K 4M2
RECRUITING
Name
Sanjida Nishat
Role
CONTACT
Phone:
905-288-5667
Extension 4296
Name
Robert Schlosser, MD
Role
PRINCIPAL_INVESTIGATOR
Mount Sinai Hospital: Leadership Sinai Centre for Diabetes
Toronto, Ontario, M5T 3L9
RECRUITING
Name
Andrej Orszag
Role
CONTACT
Phone:
416-586-4800
Extension 7625
Name
Bruce Perkins, MD
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources